← All organizations
Highest phase reached
Phase 3
Timeline
2000s
- Jan 1, 2006
Stealth BioTherapeutics Inc.— Founded
2020s
- Sep 19, 2025
elamipretide— Marketing Organization
Drugs by trial phase (3 distinct, 28 trials)
Phase 3 (1 own, 0 via acquisition)
Phase 1 (2 own, 0 via acquisition)
Indications
Studied for
- Barth Syndrome
- Corneal Dystrophies, Hereditary
- Edema
- Geographic Atrophy
- Heart Failure
- Hypertension, Renovascular
- Iridocorneal Endothelial Syndrome
- Ischemia
- Macular Degeneration
- Macular Edema
- Mitochondrial Diseases
- Mitochondrial Myopathies
- Muscular Diseases
- Optic Atrophy, Hereditary, Leber
- Optic Nerve Diseases
- Renal Artery Obstruction
- Renal Insufficiency
- Reperfusion Injury
- ST Elevation Myocardial Infarction
- Syndrome
- Wounds and Injuries
Marketed drugs (1)
Recent trials (37)
- NCT04689360Lead sponsorN/A—
- NCT06373731OfficialPhase 3May 30, 2024
- NCT06373731Lead sponsorPhase 3May 30, 2024
- NCT05168774CollaboratorPhase 1/Phase 2Mar 3, 2022
- NCT05162768Lead sponsorPhase 3Dec 31, 2021
- NCT03891875Study directorPhase 2Mar 27, 2019
- NCT03891875Lead sponsorPhase 2Mar 27, 2019
- NCT03323749Lead sponsorPhase 3Oct 27, 2017
- NCT03098797Lead sponsorPhase 2/Phase 3May 1, 2017
- NCT02976038Lead sponsorPhase 2Dec 1, 2016
- NCT02848313Lead sponsorPhase 1Oct 1, 2016
- NCT02914665Lead sponsorPhase 2Sep 1, 2016
- NCT02805790Lead sponsorPhase 2Jul 1, 2016
- NCT02788747Lead sponsorPhase 2Jun 1, 2016
- NCT02814097Lead sponsorPhase 2Jun 1, 2016
Details
- Founded
- Newton, MA, US Jan 1, 2006
- Last known activity
- Sep 19, 2025